An observational study to assess the effectiveness and safety of cemiplimab in patients with advanced non-small cell lung cancer (NSCLC) in routine clinical practice settings in Europe (CEMI-LUNG)

ENCePP Code of conduct

No information provided.

Data sources

• Data source(s):
  Other data source
• Data source(s), other:
  Prospective patient-based data collection
• Data sources (types):
  Electronic healthcare records (EHR)

Use of a Common Data Model (CDM)

• CDM mapping:
  No

Data quality specifications

• Check conformance:
  Unknown
• Check completeness:
  Unknown
• Check stability:
  Unknown
• Check logical consistency:
  Unknown

Data characterisation

• Data characterisation conducted:
  No

Procedures

No information provided.